These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 16956430)

  • 21. Activation of adenosine A3 receptors reduces ischemic brain injury in rodents.
    Chen GJ; Harvey BK; Shen H; Chou J; Victor A; Wang Y
    J Neurosci Res; 2006 Dec; 84(8):1848-55. PubMed ID: 17016854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation.
    Morello S; Petrella A; Festa M; Popolo A; Monaco M; Vuttariello E; Chiappetta G; Parente L; Pinto A
    Cancer Biol Ther; 2008 Feb; 7(2):278-84. PubMed ID: 18059189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of the adenosine A3 receptor agonist IB-MECA on sodium taurocholate-induced experimental acute pancreatitis.
    Prozorow-Krol B; Korolczuk A; Czechowska G; Slomka M; Madro A; Celinski K
    Arch Pharm Res; 2013 Sep; 36(9):1126-32. PubMed ID: 23625750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-arthritic properties of FK506 on collagen-induced arthritis in rats.
    Magari K; Nishigaki F; Sasakawa T; Ogawa T; Miyata S; Ohkubo Y; Mutoh S; Goto T
    Inflamm Res; 2003 Dec; 52(12):524-9. PubMed ID: 14991082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triphala exhibits anti-arthritic effect by ameliorating bone and cartilage degradation in adjuvant-induced arthritic rats.
    Kalaiselvan S; Rasool M
    Immunol Invest; 2015; 44(4):411-26. PubMed ID: 25942351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The stimulation of A(3) adenosine receptors reduces bone-residing breast cancer in a rat preclinical model.
    Varani K; Vincenzi F; Targa M; Paradiso B; Parrilli A; Fini M; Lanza G; Borea PA
    Eur J Cancer; 2013 Jan; 49(2):482-91. PubMed ID: 22770890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A3 adenosine receptor agonist potentiates natural killer cell activity.
    Harish A; Hohana G; Fishman P; Arnon O; Bar-Yehuda S
    Int J Oncol; 2003 Oct; 23(4):1245-9. PubMed ID: 12964011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of A3 adenosine receptors attenuates lung injury after in vivo reperfusion.
    Rivo J; Zeira E; Galun E; Matot I
    Anesthesiology; 2004 Nov; 101(5):1153-9. PubMed ID: 15505451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CGS 21680, an agonist of the adenosine (A2A) receptor, reduces progression of murine type II collagen-induced arthritis.
    Mazzon E; Esposito E; Impellizzeri D; DI Paola R; Melani A; Bramanti P; Pedata F; Cuzzocrea S
    J Rheumatol; 2011 Oct; 38(10):2119-29. PubMed ID: 21765105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective A3 adenosine receptor agonist protects against doxorubicin-induced cardiotoxicity.
    Galal A; El-Bakly WM; Al Haleem EN; El-Demerdash E
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):309-22. PubMed ID: 26676227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines.
    Naidu VG; Dinesh Babu KR; Thwin MM; Satish RL; Kumar PV; Gopalakrishnakone P
    Chem Biol Interact; 2013 Apr; 203(2):467-79. PubMed ID: 23333834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Total Saponin from Anemone flaccida Fr. Schmidt Prevents Bone Destruction in Experimental Rheumatoid Arthritis via Inhibiting Osteoclastogenesis.
    Liu C; Yang Y; Sun D; Wang C; Wang H; Jia S; Liu L; Lin N
    Rejuvenation Res; 2015 Dec; 18(6):528-42. PubMed ID: 26418168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Histamine H
    Micheli L; Durante M; Lucarini E; Sgambellone S; Lucarini L; Di Cesare Mannelli L; Ghelardini C; Masini E
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mitochondrial and caspase pathways are involved in the induction of apoptosis by IB-MECA in ovarian cancer cell lines.
    Abedi H; Aghaei M; Panjehpour M; Hajiahmadi S
    Tumour Biol; 2014 Nov; 35(11):11027-39. PubMed ID: 25095978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition.
    Madi L; Bar-Yehuda S; Barer F; Ardon E; Ochaion A; Fishman P
    J Biol Chem; 2003 Oct; 278(43):42121-30. PubMed ID: 12865431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thio-Cl-IB-MECA, a novel A₃ adenosine receptor agonist, suppresses angiogenesis by regulating PI3K/AKT/mTOR and ERK signaling in endothelial cells.
    Kim GD; Oh J; Jeong LS; Lee SK
    Biochem Biophys Res Commun; 2013 Jul; 437(1):79-86. PubMed ID: 23791876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101.
    Bar-Yehuda S; Luger D; Ochaion A; Cohen S; Patokaa R; Zozulya G; Silver PB; de Morales JM; Caspi RR; Fishman P
    Int J Mol Med; 2011 Nov; 28(5):727-31. PubMed ID: 21887476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A₃ adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action.
    Cohen S; Barer F; Bar-Yehuda S; IJzerman AP; Jacobson KA; Fishman P
    Mediators Inflamm; 2014; 2014():708746. PubMed ID: 25374446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cl-IB-MECA [2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A3 adenosine receptor.
    Ge ZD; Peart JN; Kreckler LM; Wan TC; Jacobson MA; Gross GJ; Auchampach JA
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1200-10. PubMed ID: 16985166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.